CAMBRIDGE, Mass.--(BUSINESS WIRE)--Good Start Genetics®, Inc., an innovative molecular diagnostics company harnessing a powerful, proprietary next-generation DNA sequencing (NGS) capability, today announced the publication of data from validation studies plus data from more than 11,000 patient samples tested in its clinical laboratory. These data, published in the Journal of Molecular Diagnostics, further validate the accuracy of the company’s NGS-based carrier screening test. The findings demonstrate that nearly 25% of the distinct pathogenic mutations and more than 5% of carriers detected by Good Start Genetics would have been missed by other commercially available genotyping screens utilizing traditional technologies. By arming physicians and patients with this actionable information, GoodStart Select™, the menu of carrier screening tests offered by Good Start Genetics, therefore has the potential to provide couples with greater certainty concerning their risk of conceiving a child with a debilitating or fatal inherited disease.
Help employers find you! Check out all the jobs and post your resume.
